Insider Buying: Nivalis Therapeutics, Inc. (NVLS) Major Shareholder Purchases $81,867.50 in Stock

Nivalis Therapeutics, Inc. (NASDAQ:NVLS) major shareholder Bvf Partners L. P/Il purchased 35,750 shares of the stock in a transaction on Monday, June 5th. The shares were acquired at an average cost of $2.29 per share, with a total value of $81,867.50. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Nivalis Therapeutics, Inc. (NASDAQ NVLS) traded down 1.76% on Monday, hitting $2.23. The stock had a trading volume of 40,618 shares. The company has a 50-day moving average of $2.31 and a 200-day moving average of $2.54. The company’s market cap is $34.91 million. Nivalis Therapeutics, Inc. has a 52-week low of $2.00 and a 52-week high of $9.35.

Insider Buying and Selling by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Mideast Time and is the property of of Mideast Time. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.mideasttime.com/insider-buying-nivalis-therapeutics-inc-nvls-major-shareholder-purchases-81867-50-in-stock/1773159.html.

A number of research firms have commented on NVLS. ValuEngine lowered Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research lowered Nivalis Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 5th. Cowen and Company reaffirmed a “hold” rating on shares of Nivalis Therapeutics in a research report on Wednesday, April 19th. Finally, Vetr lowered Nivalis Therapeutics from a “hold” rating to a “sell” rating and set a $2.50 price target for the company. in a research report on Monday, February 27th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.68.

Hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in shares of Nivalis Therapeutics during the fourth quarter worth about $274,000. Spark Investment Management LLC raised its stake in shares of Nivalis Therapeutics by 579.8% in the first quarter. Spark Investment Management LLC now owns 168,580 shares of the biotechnology company’s stock worth $492,000 after buying an additional 143,780 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Nivalis Therapeutics during the third quarter worth about $1,664,000. Finally, Vanguard Group Inc. raised its stake in shares of Nivalis Therapeutics by 104.7% in the first quarter. Vanguard Group Inc. now owns 411,229 shares of the biotechnology company’s stock worth $1,201,000 after buying an additional 210,325 shares during the last quarter. Hedge funds and other institutional investors own 53.09% of the company’s stock.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NVLS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.